Recursion Pharmaceuticals is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets. Their focus initially is in the orphan disease space, but their core technology has exciting applications in oncology, infectious disease, and inflammation. Their system will allow them to bring their partner’s shelved assets to market for new indications at pennies on the dollar compared to traditional drug discovery approaches.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Recursion Pharmaceuticals or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.